Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
22 03 2022
Historique:
received: 24 02 2022
revised: 15 03 2022
accepted: 17 03 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 27 4 2022
Statut: epublish

Résumé

Rapid antigen detection (RAD) tests are commonly used for the diagnosis of SARS-CoV-2 infections. However, with the continuous emergence of new variants of concern (VOC), presenting various mutations potentially affecting the nucleocapsid protein, the analytical performances of these assays should be frequently reevaluated. One hundred and twenty samples were selected and tested with both RT-qPCR and six commercial RAD tests that are commonly sold in Belgian pharmacies. Of these, direct whole-genome sequencing identified the strains present in 116 samples, of which 70 were Delta and 46 were Omicron (BA.1 and BA.1.1 sub-lineages, respectively). The sensitivity across a wide range of Ct values (13.5 to 35.7; median = 21.3) ranged from 70.0% to 92.9% for Delta strains and from 69.6% to 78.3% for Omicron strains. When taking swabs with a low viral load (Ct > 25, corresponding to <4.9 log10 copies/mL), only the Roche RAD test showed acceptable performances for the Delta strains (80.0%), while poor performances were observed for the other RAD tests (20.0% to 40.0%). All the tested devices had poor performances for the Omicron samples with a low viral load (0.0% to 23.1%). The poor performances observed with low viral loads, particularly for the Omicron strain, is an important limitation of RAD tests, which is not sufficiently highlighted in the instructions for use of these devices.

Identifiants

pubmed: 35458384
pii: v14040654
doi: 10.3390/v14040654
pmc: PMC9031584
pii:
doi:

Substances chimiques

Nucleocapsid Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Microorganisms. 2021 Apr 10;9(4):
pubmed: 33920307
Biol Methods Protoc. 2020 Jul 18;5(1):bpaa014
pubmed: 33029559
J Virol Methods. 2021 Feb;288:114024
pubmed: 33227341
J Infect. 2021 Jun;82(6):269-275
pubmed: 33882299
J Infect. 2022 May;84(5):e64-e66
pubmed: 35217106
J Clin Med. 2021 Jan 13;10(2):
pubmed: 33450853
J Clin Virol. 2021 Nov;144:104985
pubmed: 34560340
Lancet Infect Dis. 2021 Sep;21(9):e290-e295
pubmed: 33636148
Med Microbiol Immunol. 2021 Dec;210(5-6):263-275
pubmed: 34415422
Ann Intern Med. 2022 May;175(5):682-690
pubmed: 35286144
J Clin Virol. 2021 Aug;141:104900
pubmed: 34171548
Int J Infect Dis. 2022 Jan;114:112-114
pubmed: 34758391
Viruses. 2022 Mar 06;14(3):
pubmed: 35336950
Clin Chem Lab Med. 2020 Oct 7;58(12):1993-2000
pubmed: 33027042
EClinicalMedicine. 2021 Jul;37:100954
pubmed: 34127960
Nature. 2022 Mar;603(7902):715-720
pubmed: 35104836

Auteurs

Jean-Louis Bayart (JL)

Department of Laboratory Medicine, Clinique Saint-Pierre, 1340 Ottignies, Belgium.

Jonathan Degosserie (J)

COVID-19 Federal Testing Platform and NGS Surveillance Consortium, CHU UCL Namur, 5530 Yvoir, Belgium.
Department of Laboratory Medicine, Université Catholique de Louvain, CHU UCL Namur, 5530 Yvoir, Belgium.

Julien Favresse (J)

Department of Laboratory Medicine, Clinique Saint-Luc, 5004 Namur, Belgium.
Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, 5000 Namur, Belgium.

Constant Gillot (C)

Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, 5000 Namur, Belgium.

Marie Didembourg (M)

Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, 5000 Namur, Belgium.

Happy Phanio Djokoto (HP)

Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, 5000 Namur, Belgium.

Valérie Verbelen (V)

Department of Laboratory Medicine, Clinique Saint-Pierre, 1340 Ottignies, Belgium.

Gatien Roussel (G)

Department of Laboratory Medicine, Clinique Saint-Pierre, 1340 Ottignies, Belgium.

Céline Maschietto (C)

COVID-19 Federal Testing Platform and NGS Surveillance Consortium, CHU UCL Namur, 5530 Yvoir, Belgium.
Department of Laboratory Medicine, Université Catholique de Louvain, CHU UCL Namur, 5530 Yvoir, Belgium.

François Mullier (F)

Department of Laboratory Medicine, Université Catholique de Louvain, CHU UCL Namur, 5530 Yvoir, Belgium.

Jean-Michel Dogné (JM)

Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, 5000 Namur, Belgium.

Jonathan Douxfils (J)

Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, 5000 Namur, Belgium.
Qualiblood S.A., 5000 Namur, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH